Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Treasury Shares (2021 - 2025)

Tarsus Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Treasury Shares at $1.8 million for Q4 2025, down 8.3% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 8.3% YoY), and the annual figure for FY2025 was $1.8 million, down 8.3%.
  • Treasury Shares for Q4 2025 was $1.8 million at Tarsus Pharmaceuticals, roughly flat from $1.7 million in the prior quarter.
  • Over the last five years, Treasury Shares for TARS hit a ceiling of $2.0 million in Q1 2024 and a floor of $17251.0 in Q4 2021.
  • Median Treasury Shares over the past 5 years was $1.7 million (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Treasury Shares: surged 3095.51% in 2022 and later plummeted 65.05% in 2025.
  • Tarsus Pharmaceuticals' Treasury Shares stood at $17251.0 in 2021, then surged by 3095.51% to $551258.0 in 2022, then skyrocketed by 209.97% to $1.7 million in 2023, then grew by 12.09% to $1.9 million in 2024, then dropped by 8.3% to $1.8 million in 2025.
  • The last three reported values for Treasury Shares were $1.8 million (Q4 2025), $1.7 million (Q3 2025), and $692623.0 (Q2 2025) per Business Quant data.